# Synergistic Anticancer Activity of Cannabinoids and Terpenes Against Triple-Negative Breast Cancer Resistance

**Authors:** Mounika Aare, Jassy Mary Lazarte, Aakash Nathani, Breana Boirie, Tamiel N. Turley, John A. Copland, Mandip Singh

PMC · DOI: 10.3390/ijms27062730 · International Journal of Molecular Sciences · 2026-03-17

## TL;DR

This study shows that combining cannabinoids with the terpene β-caryophyllene can effectively fight aggressive breast cancer that resists traditional treatments.

## Contribution

The novel contribution is demonstrating that β-caryophyllene synergistically enhances the anticancer effects of cannabinoids in resistant triple-negative breast cancer models.

## Key findings

- Combining cannabichromene with β-caryophyllene significantly reduced cancer cell survival and migration in resistant TNBC models.
- The treatment induced cell cycle arrest and apoptosis while suppressing key cancer-promoting proteins and pathways.
- In vivo experiments showed the combination inhibited tumor growth more effectively than single-agent treatments.

## Abstract

Triple-negative breast cancer (TNBC) remains highly aggressive and refractory to conventional treatments, underscoring the need for novel combination strategies. Here, we employed 2D and 3D in vitro models, transcriptomic profiling, and in vivo xenograft studies to evaluate the anticancer efficacy of cannabinoids combined with the terpene β-caryophyllene (BC) in resistant TNBC models. Among the tested cannabinoids, cannabichromene (CBC) exhibited the greatest potency, and its combination with BC at sub-toxic concentrations significantly reduced IC50 values, enhanced cytotoxicity in spheroids, and suppressed colony formation and migration. The combination treatment induced pronounced G1 cell cycle arrest and increased apoptotic cell death. Western blot analyses revealed downregulation of PARP, Survivin, mTOR, Vimentin, Glypican-5, and PD-L1, while RNA sequencing demonstrated suppression of proliferative and migratory signaling pathways alongside activation of apoptosis, autophagy, and ferroptosis-related pathways. In vivo, CBC + BC significantly inhibited tumor growth in MDA-MB-231 xenografts, outperforming single-agent treatments. Collectively, these findings demonstrate that BC synergistically enhances cannabinoid activity, yielding superior antiproliferative and anti-migratory effects, and highlight this combination as a promising therapeutic strategy for resistant TNBC.

## Linked entities

- **Proteins:** PARP1 (poly(ADP-ribose) polymerase 1), birc5a (baculoviral IAP repeat containing 5a), MTOR (mechanistic target of rapamycin kinase), PRELID1 (PRELI domain containing 1), Gpc5 (glypican 5), CD274 (CD274 molecule)
- **Chemicals:** cannabichromene (PubChem CID 30219), β-caryophyllene (PubChem CID 5281515)
- **Diseases:** triple-negative breast cancer (MONDO:0005494)

## Full-text entities

- **Genes:** MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, PARP1 (poly(ADP-ribose) polymerase 1) [NCBI Gene 142] {aka ADPRT, ADPRT 1, ADPRT1, ARTD1, PARP, PARP-1}, GPC5 (glypican 5) [NCBI Gene 2262], VIM (vimentin) [NCBI Gene 7431], CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}
- **Diseases:** tumor (MESH:D009369), TNBC (MESH:D064726), cytotoxicity (MESH:D064420)
- **Chemicals:** BC (MESH:C024714), Terpenes (MESH:D013729), CBC (MESH:C010695), Cannabinoids (MESH:D002186)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13026563/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13026563/full.md

## References

60 references — full list in the complete paper: https://tomesphere.com/paper/PMC13026563/full.md

---
Source: https://tomesphere.com/paper/PMC13026563